Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting

AIMS: Despite the success of statins, there remains unmet clinical need in cardiovascular disease (CVD) prevention. New proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduce low-density lipoprotein cholesterol (LDL-C) by 55–65%. Two PCSK9 inhibitors, evolocumab, and alirocumab, wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Korman, Max, Wisløff, Torbjørn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843101/
https://www.ncbi.nlm.nih.gov/pubmed/28444187
http://dx.doi.org/10.1093/ehjcvp/pvx010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843101/
https://www.ncbi.nlm.nih.gov/pubmed/28444187
http://dx.doi.org/10.1093/ehjcvp/pvx010

Ejemplares similares